Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2129-2136

  Li, Jun ^a   Bi, Lintao ^a   Lin, Yumei ^a   Lu, Zhenxia ^a   Hou, Gang ^b  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Asymptomatic monoclonal gammopathy of undetermined significance (MGUS); Meta analysis; Methylation; Multiple myeloma; p15

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DNA METHYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OVERALL SURVIVAL; P15INK4B GENE; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SURVIVAL TIME; SYSTEMATIC REVIEW; GENETICS; META ANALYSIS; METABOLISM; PROGNOSIS;

CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PROGNOSIS;

EID: 84908542375     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S71088     Document Type: Article

References (36)

1. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol. 2003; 109: 80-88.
2. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004; 4: 143-153.
3. Ghavifekr Fakhr M, Farshdousti Hagh M, Shanehbandi D, Baradaran B. DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int. 2013; 2013: 317569.
4. Delpu Y, Cordelier P, Cho WC, Torrisani J. DNA methylation and cancer diagnosis. Int J Mol Sci. 2013; 14: 15029-15058.
5. Ma X, Wang YW, Zhang MQ, Gazdar AF. DNA methylation data analysis and its application to cancer research. Epigenomics. 2013; 5: 301-316.
6. Dimopoulos K, Gimsing P, Gronbaek K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J. 2014; 4: e207.
7. Sharma A, Heuck CJ, Fazzari MJ, et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med. 2010; 2: 654-669.
8. Rollig C, Illmer T. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat Rev. 2009; 35: 425-30.
9. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
10. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346: 564-569.
11. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002; 100: 1417-1424.
12. Chim CS, Kwong YL, Liang R. Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin Lymphoma Myeloma. 2008; 8: 331-339.
13. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011; 117: 553-562.
14. Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012; 33: 1629-1638.
15. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121: 749-757.
16. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36: 842-854.
17. Braggio E, Maiolino A, Gouveia ME, et al. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol. 2010; 91: 87-96.
18. Chen W, Wu Y, Zhu J, Liu J, Tan S, Xia C. Methylation of p16 and p15 genes in multiple myeloma. Chin Med Sci J. 2002; 17: 101-105.
19. Chim CS, Kwong YL, Fung TK, Liang R. Methylation profiling in multiple myeloma. Leuk Res. 2004; 28: 379-385.
20. Fan H, Guo X, Wu Q, et al. [Detection of high methylation of p15(INK4B) and p16(INK4A) genes in multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2000; 8: 271-274. Chinese.
21. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. Leukemia. 2004; 18: 1687-1692.
22. Guillerm G, Depil S, Wolowiec D, Quesnel B. Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica. 2003; 88: 476-478.
23. Guillerm G, Gyan E, Wolowiec D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood. 2001; 98: 244-246.
24. Martin P, Garcia-Cosio M, Santon A, Bellas C. Aberrant gene promoter methylation in plasma cell dyscrasias. Exp Mol Pathol. 2008; 84: 256-261.
25. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 1997; 89: 2500-2506.
26. Seidl S, Ackermann J, Kaufmann H, et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer. 2004; 100: 2598-2606.
27. Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol. 2010; 89: 191-199.
28. Wu Q, Guo X, Fan H, et al. [P15(INK4B) gene methylation in malignant hematopoietic diseases]. Zhonghua Xue Ye Xue Za Zhi. 2000; 21: 644-646. Chinese.
29. Gonzalez M, Mateos MV, Garcia-Sanz R, et al. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia. 2000; 14: 183-187.
30. Ng MH, To KW, Lo KW, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res. 2001; 7: 1724-1729.
31. Li Y, Nagai H, Ohno T, et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 2002; 100: 2572-2577.
32. Chen CY, Tsay W, Tang JL, et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer. 2003; 37: 300-305.
33. Tasaka T, Asou H, Munker R, et al. Methylation of the p16INK4A gene in multiple myeloma. Br J Haematol. 1998; 101: 558-564.
34. Voso MT, Scardocci A, Guidi F, et al. Aberrant methylation of DAPkinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood. 2004; 103: 698-700.
35. Heuck CJ, Mehta J, Bhagat T, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013; 190: 2966-2975.
36. Wang X, Zhu YB, Cui HP, Yu TT. Aberrant promoter methylation of p15 and p16 genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis. Tumour Biol. Epub 2014 June 8.